Literature DB >> 11781624

The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.

J E Johansson1, M Brune, T Ekman.   

Abstract

The efficacy of allogeneic, haemopoietic stem cell transplantation (HSCT) is limited by concomitant toxicity. This has led to the development of less toxic, reduced intensity conditioning (RIC) protocols, whose therapeutic benefit is largely related to an associated, immunity-mediated graft-versus-malignancy effect rather than by the cytotoxic treatment itself. Murine HSCT models suggests that acute graft-versus-host disease (GVHD) increases with the intensification of the conditioning regimen mediated by loss of integrity of the gut mucosa barrier. The present study was undertaken to investigate gastro-intestinal (GI) permeability during allogeneic HSCT with RIC. In 17 patients (myeloablative conditioning in nine, RIC in eight), intestinal permeability was assessed by a (51)Cr-EDTA absorption test before the start of cytotoxic treatment the day before stem cell infusion (day -1) and 4, 7 and 14 days after stem cell infusion. Patients receiving RIC did not develop any significant increase in intestinal permeability during the transplantation course but in myeloablatively conditioned patients there was a significant increase in intestinal permeability the day before the stem cell infusion (P < 0.005), on day 4 (P < 0.005), on day 7 (P < 0.01) and on day 14 (P < 0.005) after stem cell infusion, compared with the baseline. Myeloablative conditioning also revealed increased intestinal permeability on day 7 compared with the RIC (P < 0.05). The finding of preserved intestinal-barrier function during allogeneic HSCT with RIC is discussed, with reference to the hypothesis that GI tract damage may be an important initiating event of GVHD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781624     DOI: 10.1038/sj.bmt.1703230

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

Review 1.  Intestinal microbiota-related effects on graft-versus-host disease.

Authors:  Yusuke Shono; Melissa D Docampo; Jonathan U Peled; Suelen M Perobelli; Robert R Jenq
Journal:  Int J Hematol       Date:  2015-03-27       Impact factor: 2.490

2.  Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1.

Authors:  Celalettin Ustun; Soyoung Kim; Min Chen; Amer M Beitinjaneh; Valerie I Brown; Parastoo B Dahi; Andrew Daly; Miguel Angel Diaz; Cesar O Freytes; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C Hildebrandt; Hillard M Lazarus; Taiga Nishihori; Richard F Olsson; Kristin M Page; Genovefa Papanicolaou; Ayman Saad; Sachiko Seo; Basem M William; John R Wingard; Baldeep Wirk; Jean A Yared; Miguel-Angel Perales; Jeffery J Auletta; Krishna V Komanduri; Caroline A Lindemans; Marcie L Riches
Journal:  Blood Adv       Date:  2019-09-10

3.  Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation.

Authors:  Christopher W Peterson; Kevin G Haworth; Patricia Polacino; Meei-Li Huang; Craig Sykes; Willimark M Obenza; Andrea C Repetto; Angela Kashuba; Roger Bumgarner; Stephen C DeRosa; Ann E Woolfrey; Keith R Jerome; James I Mullins; Shiu-Lok Hu; Hans-Peter Kiem
Journal:  AIDS       Date:  2015-08-24       Impact factor: 4.177

4.  Role of antioxidants in buccal mucosa cells and plasma on the incidence and severity of oral mucositis after allogeneic haematopoietic cell transplantation.

Authors:  Paul Urbain; Anna Raynor; Hartmut Bertz; Christine Lambert; Hans-Konrad Biesalski
Journal:  Support Care Cancer       Date:  2011-10-01       Impact factor: 3.603

Review 5.  Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease.

Authors:  Suze A Jansen; Edward E S Nieuwenhuis; Alan M Hanash; Caroline A Lindemans
Journal:  Mucosal Immunol       Date:  2022-06-02       Impact factor: 8.701

6.  Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.

Authors:  In-Wha Kim; Hwi-yeol Yun; Boyoon Choi; Nayoung Han; Myeong Gyu Kim; Seonyang Park; Jung Mi Oh
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

7.  Recipient NK cell inactivation and intestinal barrier loss are required for MHC-matched graft-versus-host disease.

Authors:  Sam C Nalle; H Aimee Kwak; Karen L Edelblum; Nora E Joseph; Gurminder Singh; Galina F Khramtsova; Eric D Mortenson; Peter A Savage; Jerrold R Turner
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

8.  G-CSF-primed haplo-identical HSCT with intensive immunosuppressive and myelosuppressive treatments does not increase the risk of pre-engraftment bloodstream infection: a multicenter case-control study.

Authors:  Jinhua Ren; Qiaoxian Lin; Weimin Chen; Congmeng Lin; Yuxin Zhang; Cunrong Chen; Shaozhen Chen; Xiaohong Yuan; Ping Chen; Xiaofeng Luo; Yun Lin; Lvying Shen; Mengxian Guo; Qiuru Chen; Min Xiao; Yongquan Chen; Xueqiong Wu; Yanling Zeng; Zhizhe Chen; Xudong Ma; Jianda Hu; Ting Yang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-01-26       Impact factor: 3.267

Review 9.  New strategies for prevention and treatment of graft-versus-host disease and for induction of graft-versus-leukemia effects.

Authors:  H Joachim Deeg
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

10.  Gut toxicity during hemopoietic stem cell transplantation may predict acute graft-versus-host disease severity in patients.

Authors:  Jan-Erik Johansson; Tor Ekman
Journal:  Dig Dis Sci       Date:  2007-04-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.